glp-1 drug companies Swiss Re says drugs could reduce US mortality by up to 6.4% GLP-1 Drugs and The Pharma

Cost and patient reluctance toward injectables pose significant restraints to market growth

Available from: [Google Scholar] 50.Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, et al

How is that possible

A separate study found most people who stop taking GLP-1s regain 60% of the weight they lost within a year, and eventually 75% of it, only shedding 25% of that weight in the long term

You can read a more in-depth explanation and analysis of risk from the Cleveland Clinic , but heres the bottom line: Out of an abundance of caution, anyone with a personal or family history making them more susceptible to C cell thyroid cancer (specifically) is advised not to use a GLP-1 medication

The efficacy and safety of SGLT2 inhibitor in Diabetic kidney transplant recipients